Higuchi 2012.
Trial name or title | Randomized phase III study of S‐1 plus oxaliplatin versus S‐1 plus cisplatin for first‐line treatment of advanced gastric cancer |
Methods | RCT 2 arms |
Participants | N = 685 with unresectable advanced or recurrent gastric cancer, PS 0‐2, age ≥ 20 years |
Interventions | Arm A (SOX): (oral S‐1 40 mg/m² twice a day d 1‐14 + oxaliplatin 100 mg/m² iv day 1, repeated at 3 weeks) versus Arm B (SP): (oral S‐1 40 mg/m² twice a day d 1‐ 21 + cisplatin 60 mg/m² iv day 8, repeated at 5 weeks) |
Outcomes | Progression‐free survival, response rate (RR), safety, and length of hospital stay per cycle |
Starting date | |
Contact information | Yakult Honsha Co., Ltd., Clinical Development, Medical Development Department, Pharmaceutical Division, Tel 813‐5550‐8966 Fax 813‐3248‐5502 |
Notes | The study is registered (JapicCTI‐101021) and has recruited 685 participants from January 2010 and October 2011. |